Bionomics Ltd Adr Stock Fundamentals
| BNOX Stock | USD 0.29 0.01 3.57% |
Bionomics Ltd ADR fundamentals help investors to digest information that contributes to Bionomics' financial success or failures. It also enables traders to predict the movement of Bionomics Stock. The fundamental analysis module provides a way to measure Bionomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionomics stock.
At this time, Bionomics' Other Operating Expenses is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 18.8 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 412.7 K in 2024. Bionomics | Select Account or Indicator |
Bionomics Ltd ADR Company Current Valuation Analysis
Bionomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bionomics Current Valuation | (2.08 M) |
Most of Bionomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionomics Ltd ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bionomics Ltd ADR has a Current Valuation of (2.08 Million). This is 100.01% lower than that of the Biotechnology sector and 100.04% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
Bionomics ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bionomics's current stock value. Our valuation model uses many indicators to compare Bionomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionomics competition to find correlations between indicators driving Bionomics's intrinsic value. More Info.Bionomics Ltd ADR is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Bionomics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionomics' earnings, one of the primary drivers of an investment's value.Bionomics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bionomics could also be used in its relative valuation, which is a method of valuing Bionomics by comparing valuation metrics of similar companies.Bionomics is currently under evaluation in current valuation category among its peers.
Bionomics Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | 89.10 % | ||||
| Current Valuation | (2.08 M) | ||||
| Shares Outstanding | 19.53 M | ||||
| Shares Owned By Insiders | 33.91 % | ||||
| Shares Owned By Institutions | 16.22 % | ||||
| Number Of Shares Shorted | 190.27 K | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 386.72 X | ||||
| Revenue | 20 K | ||||
| Gross Profit | (18.96 M) | ||||
| EBITDA | (9.84 M) | ||||
| Net Income | (15.49 M) | ||||
| Cash And Equivalents | 33.56 M | ||||
| Cash Per Share | 4.46 X | ||||
| Total Debt | 239.62 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.46 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (9.62 M) | ||||
| Short Ratio | 0.13 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 15.37 | ||||
| Beta | -0.069 | ||||
| Market Capitalization | 5.75 M | ||||
| Total Asset | 27.65 M | ||||
| Retained Earnings | (177.98 M) | ||||
| Working Capital | 9.36 M | ||||
| Net Asset | 27.65 M |
About Bionomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionomics Ltd ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionomics Ltd ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -33.1 K | -34.8 K | |
| Total Revenue | 20 K | 19 K | |
| Cost Of Revenue | 434.4 K | 412.7 K | |
| Stock Based Compensation To Revenue | 85.70 | 89.99 | |
| Sales General And Administrative To Revenue | 258.84 | 271.79 | |
| Research And Ddevelopement To Revenue | 882.45 | 926.57 | |
| Ebit Per Revenue | -1.8 K | -1.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bionomics Stock Analysis
When running Bionomics' price analysis, check to measure Bionomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionomics is operating at the current time. Most of Bionomics' value examination focuses on studying past and present price action to predict the probability of Bionomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionomics' price. Additionally, you may evaluate how the addition of Bionomics to your portfolios can decrease your overall portfolio volatility.